Allogene's CEO David Chang to Depart Amid Industry Developments
In a significant shift for Allogene, CEO David Chang is stepping down. This news comes alongside Pfizer's major investment in Chinese pharmaceuticals and WHO's efforts in response to the Ebola outbreak.
Editorial Staff
1 min read
Updated 11 days ago
Allogene Therapeutics is set to undergo leadership changes as CEO David Chang announces his departure. This transition comes at a time of notable activity in the biotech sector.
Pfizer has recently made headlines with its substantial investment aimed at acquiring Chinese pharmaceutical companies, indicating a strategic expansion into that market.
Additionally, the World Health Organization is mapping out an experimental response to the ongoing Ebola outbreak, highlighting the urgent need for effective interventions in global health crises.